Prevalence of glucosamine and omega-3 fatty acid use and characteristics of users among mid-age women: Analysis of a nationally representative sample of 10,638 women
- 211 Downloads
There has been a dramatic increase in the use of dietary supplements over the last few decades and both omega-3 fatty acids and glucosamine are two of the best-selling dietary supplements in many countries. An understanding of omega-3 fatty acids and glucosamine consumption is of significance to health care providers and for future health promotion activities.
This research involved analysis of data collected from a nationally-representative sample of Australian women as part of the Australian Longitudinal Study on Women’s Health (ALSWH). Participants’ use of omega-3 fatty acids (FA), glucosamine, their demographics, health status and health care utilisation were measured. Analysis included logistic regression modelling.
Of the 10,638 women in the study, 26.8% reported use of omega-3 FA and 15.9% glucosamine. Women with osteoarthritis (OR=2.529; 95% CI: 2.190, 2.921), other arthritis (OR= 1.618; 95% CI: 1.375, 1.905), and joint pain (OR= 2.699; 95% CI: 2.305, 3.160) were more likely to use glucosamine (all p<0.001). In contrast, those with diabetes (OR= 0.471; 95% CI: 0.343, 0.646) or depression (OR= 0.764; 95% CI: 0.657, 0.887) were less likely to use glucosamine (both p<0.001). Women with osteoarthritis (OR=1.481; 95% CI: 1.297, 1.691) and joint pain (OR= 1.456; 95% CI: 1.306, 1.622) were more likely to use omega-3 FA (all p<0.001).
Substantial prevalence rates for use of glucosamine and omega-3 FA amongst mid-aged women highlights the need for health practitioners and policymakers to be mindful of the possible significant role of such supplement use as part of patient health-seeking behaviours.
Key wordsGlucosamine omega-3 fatty acids women arthritis joint pain
- 1.Gahche J, Bailey R, Burt V, Hughes J, Yetley E, Dwyer J, Picciano MF, McDowell M, Sempos C. «Dietary Supplement Use Among U.S. Adults Has Increased Since NHANES III (1988–1994).» Centers for Disease Control and Prevention, Atlanta 2011.Google Scholar
- 4.Hale WA, Joubert JD, Kalula S. “Aging populations and chronic illness.” In: WH Markle, MA Fisher, J Raymond & A Smego (eds) in Understanding Global Health, McGraw-Hill, New York, 2007; pp 208–229.Google Scholar
- 7.Barnes PM, Bloom B, Nahin RL. «Complementary and Alternative Medicine Use Among Adults and Children: United States, 2007 « U.S. Department of Health and Human Services, Division of Health Interview Statistics, Centers for Disease Control and Prevention, National Center for Health Statistics, Hyattsville 2008.Google Scholar
- 9.Brown J, Morgan T, Adams J, Grunseit A, Toms M, Roufogalis B, Kotsirilos V, Pirotta M, Williamson M. «Complementary Medicines Information Use and Needs of Health Professionals: General Practitioners and Pharmacists.» Aust Prescr 2008.Google Scholar
- 10.Adams J, Sibbritt D, Lui CW, Broom A, Wardle J. «Omega-3 supplement use: A secondary analysis of 266,848 Australians aged 45 years and older.» BMJ Open 2013; 3 (4).Google Scholar
- 15.Black C, Clar C, Henderson R, Maceachern C, McNamee P, Quayyum Z, Royle P, Thomas S. «The clinical effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of the knee: a systematic review and economic evaluation.» Health Technol Assess 2009; 13: 1–148.CrossRefPubMedGoogle Scholar
- 21.Towheed T, Maxwell L, Anastassiades TP, Shea B, Houpt JB, Welch V, Hochberg MC, Wells GA. «Glucosamine therapy for treating osteoarthritis.» Cochrane Database Syst Rev 2005; DOI: 10.1002/14651858.CD002946.pub2.Google Scholar
- 27.Chowdhury R, Stevens S, Gorman D, Pan A, Warnakula S, Chowdhury S, Ward H, Johnson L, Crowe F, Hu FB, Franco, OH. «Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: Systematic review and meta-analysis.» BMJ 2012; 345.Google Scholar
- 29.Filion KB, El Khoury F, Bielinski M, Schiller I, Dendukuri N, Brophy JM. «Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials.» BMC Cardiovasc Disord 2010; 10.Google Scholar
- 33.Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, Kupelnick B, Jordan HS, Lau J. «N-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review.» Am J Clin Nutr 2006; 84: 5–17.PubMedGoogle Scholar
- 35.National Heart Foundation of Australia. «Position Statement: Fish, Fsh Oils, n-3 Polyunsaturated Fatty Acids and Cardiovascular Health.» National Heart Foundation of Australia, Sydney. 2008.Google Scholar
- 41.Montgomery P, Richardson AJ. «Omega-3 fatty acids for bipolar disorder.» Cochrane Database Syst Rev 2008 Art. No.: CD005169. DOI: 10.1002/14651858.CD005169. pub2.Google Scholar
- 42.Thien FCK, De Luca S, Woods RK, Abramson MJ. «Dietary marine fatty acids (fish oil) for asthma in adults and children.» Cochrane Database Syst Rev 2002; Art. No.: CD001283. DOI: 10.1002/14651858.CD001283.Google Scholar
- 43.Oliver C, Everard M, N’Diaye T. «Omega-3 fatty acids (from fish oils) for cystic fibrosis.» Cochrane Database Syst Rev 2007.Google Scholar
- 44.Agency for Healthcare Research and Quality. «Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis.» Agency for Healthcare Research and Quality, Rockville 2004.Google Scholar
- 45.James S, Montgomery P, Williams K. «Omega-3 fatty acids supplementation for autism spectrum disorders (ASD).» Cochrane Database Syst Rev 2011.Google Scholar
- 46.Sydenham E, Dangour AD, Lim WS. «Omega 3 fatty acid for the prevention of cognitive decline and dementia.» Cochrane Database Syst Rev 2012.Google Scholar
- 47.Braun LA, Tiralongo E, Wilkinson JM, Spitzer O, Bailey M, Poole S, Dooley M. «Perceptions, use and attitudes of pharmacy customers on complementary medicines and pharmacy practice.» BMC Complement Altern Med 2010; 10.Google Scholar
- 54.Australian Institute of Health and Welfare. «National Health Data Dictionary: Version 6.0 Standard Questions on the Use of Tobacco among Adults.» Australian Institute of Health and Welfare, Canberra. 1997.Google Scholar
- 55.National Health and Medical Research Council of Australia. «Australia Alcohol Guidelines: Health Risks and Benefits.» National Health and Medical Research Council of Australia, Canberra. 2001.Google Scholar
- 56.World Health Organization. «Guideline for ATC Classification and DD Assignment.» World Health Organization, Geneva. 2011.Google Scholar